ArticleBMC microbiology2025
XGBoost-based urinary microbial signatures enable non-invasive diagnosis and prognosis for urothelial carcinoma.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial.Cancers · 2026Article
- Development and validation of machine learning models for diagnosing hepatocellular carcinoma risk and survival in patients with diabetic cirrhosis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUrothelial carcinoma (UC) is the most common malignant tumor of the urinary system, characterized by high incidence and recurrence rates, posing a serious threat to human health. While previous studies have linked urinary microbiota alterations to bladder cancer, little is known about the broader spectrum of UC subtypes or their clinical implications. To address this gap, we analyzed microbiota profiles across multiple UC subtypes, incorporating microbial network analyses and machine learning to establish diagnostic models and identify prognostic biomarkers.
methodA total of 112 subjects were enrolled for 16 S rDNA sequencing of clean-catch midstream urine samples, including 63 patients with bladder cancer (BCA), 29 with Upper Tract Urothelial Carcinoma (UTUC), 9 with renal pelvis cancer (RPC), and 40 healthy controls (HC). Microbial diversity, community networks, and clinical associations were analyzed. An XGBoost-based diagnostic model was developed with a 70/30 train-test split, cross-validation, and external validation. Model interpretability was assessed with the SHAP algorithm.
resultsUC groups showed elevated α-diversity versus HC, with consistent enrichment of Streptococcus and Clostridium. Microbial structure networks significantly differed in tumors. A urinary microbiota-based diagnostic model achieved high accuracy for BCA detection (AUC = 0.927), and Lachnospiraceae family members showed potential prognostic value.
conclusionOur study illuminates the microbial profiles in the UC and suggests that urinary microbiota signatures represent promising non-invasive independent biomarker for the diagnosis and prognosis of UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.